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Excessive accumulation of fibrillar collagens is a
hallmark of the cutaneous fibrosis in both systemic and
localized scleroderma. Turnover of the collagenous
extracellular matrix is dependent on the balance between
collagenolytic matrix metalloproteinases and their
specific inhibitors. We have examined the expression
of the novel, matrix associated tissue inhibitor of
metalloproteinases-3 (TIMP-3) in normal and sclero-
derma skin fibroblasts in culture and in vivo. The levels
of TIMP-3 mRNA were elevated up to 2.5-fold in five
of seven systemic sclerosis fibroblast strains, whereas
TIMP-1 mRNA expression was elevated up to 1.8-fold
in two and TIMP-2 mRNA expression up to 1.8-fold in
two systemic sclerosis strains. Using in situ hybridization,
TIMP-3 mRNA was detected in seven of 12 localized
scleroderma skin samples, specifically in fibroblasts
Excessive accumulation of extracellular matrix (ECM),especially fibrillar collagens of type I and type III, is ahallmark of cutaneous fibrosis in both systemic scleroderma(systemic sclerosis, SSc) and localized scleroderma (forreviews, see Ka¨ha¨ri, 1993; Varga and Jimenez, 1996). In
these two forms of dermal fibrosis an early perivascular inflammatory
reaction is followed by enhanced deposition of collagenous ECM in
the dermal layer (LeRoy et al, 1988). It has been shown that fibroblasts
cultured from the affected skin of patients with both SSc and localized
scleroderma produce increased amounts of several connective tissue
components, mainly of type I collagen (LeRoy, 1974; Uitto et al,
1979) as a result of transcriptional activation of the corresponding
genes (Ka¨ha¨ri et al, 1984, 1987). It has also been documented that in
the lesional skin of patients with localized scleroderma or SSc, a
subpopulation of fibroblasts shows activation of type I collagen expres-
sion (Ka¨ha¨ri et al, 1988; Scharffetter et al, 1988), and that these activated
fibroblasts often localize to the proximity of mononuclear inflammatory
cells expressing transforming growth factor-β (TGF-β) (Kulozik et al,
1990; Gruschwitz et al, 1990).
The net accumulation of ECM in tissue is dependent on the balance
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within fibrotic collagen fibers or in the vicinity of
inflammatory cells. TIMP-1 mRNA was detected in three
of eight scleroderma skin samples in fibroblasts adjacent
to inflammatory cells. The expression of TIMP-3 mRNA
by systemic sclerosis and normal skin fibroblasts was
enhanced to a similar extent (by 8.6- and 8.1-fold,
respectively) by transforming growth factor-b, and sup-
pressed down to 34 and 54%, respectively, by tumor
necrosis factor-a. Specific activation of TIMP-3 gene
expression in scleroderma skin fibroblasts in culture and
in vivo suggests a role for TIMP-3 in the pathogenesis of
dermal fibrosis via inhibition of turnover of fibrotic
dermal extracellular matrix, possibly due to upregulation
of TIMP-3 expression by transforming growth factor-b.
Keywords: fibrosis/matrix metalloproteinase. J Invest Dermatol
110:416–421, 1998
between the synthesis and the degradation of matrix components
by matrix metalloproteinases (MMP), a family of zinc-dependent
endopeptidases collectively capable of degrading essentially all ECM
components. At present, the MMP gene family contains 16 members,
which according to their substrate specificity and structure can be
divided into subgroups of collagenases, gelatinases, stromelysins, and
membrane-type MMP (Ka¨ha¨ri and Saarialho-Kere, 1997). Of these,
the members of the collagenase subfamily, collagenase-1 (MMP-1),
neutrophil collagenase (MMP-8), and collagenase-3 (MMP-13), are
the principal secreted neutral proteinases capable of degrading fibrillar
collagens of types I and III. The activity of MMP is specifically
inhibited by tissue inhibitors of metalloproteinases (TIMP), which bind
to activated MMP with 1:1 molar stoichiometry (Apte et al, 1995). At
present, the TIMP gene family consists of four members (Greene et al,
1996; Ka¨ha¨ri and Saarialho-Kere, 1997). Of these, TIMP-1 and TIMP-
2 are produced in soluble form, but their expression is differently
regulated. Production of TIMP-1 is enhanced by growth factors, e.g.,
TGF-β, whereas the expression of TIMP-2 is constitutive and not
susceptible to regulation by most growth factors. In contrast, TIMP-3
is not soluble, but is associated with ECM in vitro and in vivo (Leco
et al, 1994). The expression of TIMP-3 in cultured cells is induced by
mitogenic stimuli, e.g., serum, epidermal growth factor (EGF), and
TGF-β specifically in the G1 phase of the cell cycle (Leco et al, 1994;
Wick et al, 1994, 1995). Although TIMP-3 mRNA can be detected
in several adult human tissues, e.g., placenta, heart, brain, lung, liver,
skeletal muscle, kidney, and pancreas (Apte et al, 1994; Wick et al,
1995), in normal adult human skin the expression of TIMP-3 mRNA
is limited to growing hair follicles and stromal cells surrounding sweat
glands (Airola et al, 1998).
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Table I. Expression of proa(I) collagen, TIMP-3, TIMP-2, and TIMP1 mRNA in SSc skin fibroblastsa
mRNA, ratio affected/nonaffected
Type/duration of
Patient Age/sex SSc (mo)b proα(I) collagen TIMP-3 TIMP-2 TIMP-1
SSc-1 52/M dcSSc/84 2.50 2.37 0.96 0.92
SSc-2 47/F dcSSc/18 1.75 1.31 0.92 0.68
SSc-3 35/F IcSSc/12 1.31 2.45 1.75 1.79
SSc-4 40/F dcSSc/48 0.61 0.75 1.57 0.78
SSc-5 47/F dcSSc/24 1.18 2.50 0.76 1.48
SSc-6 30/F dcSSc/36 1.11 1.28 0.71 1.11
SSc-7 48/F IcSSc/48 0.56 0.47 1.15 0.83
a The levels of proα(I) collagen, TIMP-3, TIMP-2, and TIMP-1 mRNA were determined by northern blot hybridizations, quantitated by densitometry, corrected for GADPH mRNA
levels in each sample, and the ratio (affected/nonaffected) for each mRNA was calculated.
bdcSSc, diffuse cutaneous systemic scleroderma; IcSSc, limited cutaneous systemic scleroderma.
A role for reduced turnover of the fibrotic ECM in the pathogenesis
of cutaneous fibrosis has been suggested by studies showing that SSc
skin fibroblasts in culture produce less MMP-1 (Takeda et al, 1994)
and stromelysin-1 (MMP-3) and increased amounts of TIMP-1, as
compared with control skin fibroblasts (Bou Gharios et al, 1994; Kirk
et al, 1995; Kikuchi et al, 1997). In addition, elevated TIMP-1 serum
levels have been shown to correlate with the disease activity in SSc
patients (Kikuchi et al, 1995). In this study we show that activated
scleroderma skin fibroblasts express elevated levels of TIMP-3 mRNA
in culture and in vivo. In addition, the expression of TIMP-3 mRNA
in systemic scleroderma and nonaffected skin fibroblasts was stimulated
by TGF-β and suppressed by tumor necrosis factor-α (TNF-α).
Activation of TIMP-1 expression was also detected in scleroderma
skin in vivo, although to a lesser extent than TIMP-3. These results
provide evidence that TIMP-3 may play a role in the pathogenesis of
dermal fibrosis in systemic and localized scleroderma by inhibiting the
turnover of fibrotic ECM.
MATERIALS AND METHODS
Cell cultures Skin fibroblast cultures were started from punch biopsies
obtained from the margin of the fibrotic clinically affected skin in the forearm,
wrist, or finger, and from symmetrically located nonaffected skin of seven
patients (six females and one male), five with diffuse cutaneous SSc (dcSSc)
and two with limited cutaneous SSc (lcSSc) (Table I), diagnosed according
to the American Rheumatism Association criteria (American Rheumatism
Association, 1980). Patients had a mean age of 43 y (range 30–52 y) and a
mean disease duration of 38 mo (range 12–84 mo). For experiments, nonaffected
and SSc fibroblasts were used in subcultures 3–5. Cells were maintained in
Dulbecco’s modification of Eagle’s medium (Flow Laboratories, Irvine, U.K.)
supplemented with 10% fetal calf serum (Flow Laboratories), 2 mM glutamine,
100 IU penicillin-G per ml, and 100 µg streptomycin per ml. For experiments,
the cells were maintained in Dulbecco’s modification of Eagle’s medium
supplemented with 1% fetal calf serum for 18 h. Thereafter, TNF-R55 specific
human TNF-α (double mutant R32WS86T, Barbara et al, 1994) (kindly
provided by Dr. Walter Fiers, University of Gent, Belgium), human recombinant
interleukin-1β (IL-1β, Boehringer, Mannheim, Germany), or bovine TGF-β1
(kindly provided by Dr. David R. Olsen, Celtrix, Santa Clara, CA) were added
and the incubations were continued for 24 h.
RNA analysis Total cellular RNA was isolated from cells using the single
step method (Chomczynski and Sacchi, 1987). Aliquots of total RNA (10–
15 µg) were fractionated on 0.8% agarose gel containing 2.2 M formaldehyde,
transferred to Zeta probe filter (Bio-Rad, Richmond, CA) by vacuum transfer
(VacuGene XL; LKB, Bromma, Sweden) and immobilized by heating at 80°C
for 30 min. The filters were prehybridized for 2 h and subsequently hybridized
for 20 h with 32P-labeled cDNA. The filters were then washed, the final
stringency being 0.1 3 standard saline citrate-0.1% sodium dodecyl sulfate at
60°C (Thomas, 1980). For hybridizations, cDNA fragments corresponding to
the coding regions of human TIMP-3 (636 bp) (Urı´a et al, 1994), TIMP-2
(663 bp) (Stetler-Stevenson et al, 1990), and TIMP-1 (624 bp) (Carmichael
et al, 1986) were generated by reverse transcriptase polymerase chain reaction
with specific sense and anti-sense oligonucleotide primers using normal human
skin fibroblast RNA as template, and their identity was verified by nucleotide
sequencing. In addition, a 0.7 kb human proα1 (I) collagen cDNA (Ma¨kela¨
et al, 1988) and a 1.3 kb rat glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA (Fort et al, 1985) were used. The 32P-cDNA-mRNA hybrids
were visualized with autoradiography, quantitated with densitometry, and
corrected for the levels of GAPDH mRNA in each sample.
In situ hybridizations Formalin-fixed, paraffin-embedded skin specimens of
11 patients with localized scleroderma and one with systemic scleroderma
(Table II) were obtained from the Department of Dermatology, Helsinki
University Central Hospital, Finland. Biopsies were taken from 3 mo to 3 y
old lesions in different parts of the body and examined by an experienced
dermatopathologist to confirm the clinical diagnosis by histopathology (Lever
and Schaumburg-Lever, 1990). The samples were divided into initial, middle,
and late stage of the disease based on the degree of inflammation (the number
of lymphocytic inflammatory infiltrates between collagen bundles and around
blood vessels) and fibrosis (the presence of thickened collagen bundles in the
dermal layer, atrophic eccrine glands).
For in situ hybridizations, the human TIMP-3 cDNA fragment utilized for
northern blot hybridizations was used (Airola et al, 1998). The production and
specificity of the TIMP-1 probe has been described previously (Carmichael
et al, 1986; Sudbeck et al, 1992). RNA probes transcribed from TIMP-3 and
TIMP-1 cDNA in sense orientation were used as controls for nonspecific
hybridization. By FASTA alignment, highest similarities between the probes
used and other members of the TIMP family were 53–55%, making cross-
hybridization at high stringency unlikely. For detection of collagenase-1
(MMP-1) mRNA, a 550 bp EcoRV-SmaI fragment from the 59-end of human
MMP-1 cDNA (Goldberg et al, 1986) was used, and for detection of collagenase-
3 (MMP-13) mRNA, we used a 490 bp ApaI fragment from the coding region
of human MMP-13 cDNA (Johansson et al, 1997a). The specificities of these
probes have been documented previously (Goldberg et al, 1986; Johansson et al,
1997a, b; Vaalamo et al, 1997). In vitro transcribed anti-sense and sense RNA
probes were labeled with α-35S-labeled UTP (Saarialho-Kere et al, 1993).
Sections were hybridized with probes (2.5–4 3 104 cpm hybridization buffer
per µl) and washed under stringent conditions, including treatment with
RNase A, as described (Prosser et al, 1989; Saarialho-Kere et al, 1993). After
autoradiography for 10–30 d, the photographic emulsion was developed and
the slides were stained with hematoxylin and eosin. Samples of breast carcinomas
were used as positive controls for the expression of TIMP-3 mRNA (Urı´a
et al, 1994).
Statistical analysis Statistical significance was determined by Student’s t test.
RESULTS
Increased TIMP-3 mRNA expression in systemic scleroderma
skin fibroblasts It has recently been shown that SSc skin fibroblasts
produce increased amounts of TIMP-1, as compared with control skin
fibroblasts (Kirk et al, 1995; Kikuchi et al, 1997). To elucidate the role
of TIMP-3 in the pathogenesis of dermal fibrosis in scleroderma, we
first examined the abundance of TIMP-3 mRNA in dermal fibroblast
cultures established from clinically affected and nonaffected skin of
seven patients with SSc. As shown in Fig 1(a), both scleroderma and
nonaffected skin fibroblasts express three specific TIMP-3 mRNA, the
sizes of which (4.8, 2.8, and 2.4 kb) are in accordance with previous
observations on other cell types (Wick et al, 1994; Airola et al, 1998).
In three of seven SSc fibroblast strains (SSc-1, SSc-3, and SSc-5) the
expression of TIMP-3 mRNA was clearly elevated (2.4–2.5-fold), and
in two additional SSc fibroblast strains (SSc-2 and SSc-6) the expression
was slightly elevated (1.3-fold), as compared with the corresponding
nonaffected skin fibroblasts (Fig 1a, Table I). In two of these SSc
418 MATTILA ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Table II. Expression of TIMP-3 and TIMP-1 mRNA in scleroderma skina
mRNA
Location and age (mo)
Skin sample Age/sex of the lesion Histology and aspect of the lesionb TIMP-3 TIMP-1
1 43/F trunk, 6 I, soft, lilac ring, indurated 3 mo after biopsy 2 2
2 22/F back, 36 M, atrophic, pigmented 1 ND
3 27/M abdomen, 4 M, indurated 2 ND
4 21/F abdomen, 12 M, soft, erythematous, pigmented 1 2
5 12/F arm, 3 M, indurated 1 1
6 45/F upper back, 3 M, atrophic, pigmented 2 2
7 44/M trunk, 6 L, indurated, pigmented, lilac 11 1
8 61/F breast, 7 L, light yellow with lilac ring 11 ND
9 61/M waist, 4 L, livid, indurated 2 ND
10 85/F abdomen, 24 L, indurated 1 1
11 30/M back, 6 L, indurated, hard, light-colored 1 2
12* 44/F foot, 6 L, indurated, thick, light-colored 2 2
aExpression of TIMP-3 and TIMP-1 mRNA in the lesional skin of 11 patients with localized scleroderma and one with SSc* was determined by in situ hybridization and estimated in
range from 2 to 11. ND, not determined.
bHistology of the lesion: I, initial stage, slight fibrosis, strong inflammation; M, middle stage, fibrosis, slight inflammation; L, late stage, abundant fibrosis, moderate inflammation;
estimated as described in the Materials and Methods.
Figure 1. Activation of TIMP-3 expression in SSc skin fibroblasts and
inhibition of TIMP-3 expression by TNF-R55 specific TNF-a. (a)
Fibroblasts cultured from nonaffected (NA-1) and fibrotic (SSc-1) skin of a
patient with systemic sclerosis were maintained in Dulbecco’s modification of
Eagle’s medium containing 1% fetal calf serum for 18 h, and subsequently
treated with IL-1β (5 U per ml) or TNF-R55 specific TNF-α (20 ng per ml)
for 24 h, as indicated. Aliquots of total RNA (15 µg) were analyzed for the
levels of proα1 (I) collagen, TIMP-3, TIMP-2, TIMP-1, and GAPDH mRNA
with northern blot hybridizations. (b,c) The mRNA levels of TIMP-3, TIMP-
2, TIMP-1, and proα1 (I) collagen determined with northern blot hybridizations
were quantitated by densitometric scanning of the autoradiographs and corrected
for the levels of GAPDH mRNA. The bars show the mean percentage 6 SD
of the mRNA levels of (b) seven nonaffected and SSc fibroblast strains treated
with TNF-R55 specific TNF-α, or (c) six nonaffected and SSc fibroblast strains
treated with IL-1β, relative to the mRNA levels in untreated corresponding
fibroblast strains (100%). *p , 0.05, **p , 0.005, ***p , 0.001. There was
no significant difference in response between nonaffected and SSc fibroblasts.
fibroblast strains (SSc-1 and SSc-2), proα1 (I) collagen mRNA levels
were also elevated (2.5- and 1.8-fold, respectively) (Fig 1a, Table I).
The expression of 0.9 kb TIMP-1 mRNA was also somewhat (1.8-
and 1.5-fold) enhanced in two SSc fibroblast strains (SSc-3 and SSc-
5, respectively), both of which also show activation of TIMP-3
expression (Table I). The abundance of two TIMP-2 mRNA (3.5
and 1.0 kb) was also elevated (1.8- and 1.6-fold) in two SSc fibroblast
strains (SSc-3 and SSc-4, respectively) (Table I); however, coordinate
activation of the expression of TIMP-3, TIMP-2, and TIMP-1 was
detected in only one SSc fibroblast strain (SSc-3) (Table I).
TNF-a inhibits TIMP-3 mRNA expression in nonaffected and
SSc skin fibroblasts We have recently shown that TNF-α inhibits
type I collagen and enhances collagenase-1 (MMP-1) gene expression
by normal and SSc skin fibroblasts in culture via the 55 kDa TNF-α
receptor (TNF-R55) (Westermarck et al, 1995). In this context we
examined the effect of TNF-R55 specific TNF-α on the expression
of TIMP-3 in both SSc and nonaffected skin fibroblasts. As shown in
Fig 1(a), treatment with TNF-R55 specific TNF-α resulted in a
marked reduction in the levels of TIMP-3 mRNA in both SSc and
nonaffected skin fibroblasts. The mean TIMP-3 mRNA levels in seven
SSc fibroblast strains treated with TNF-α were 34% (p , 0.005) of
the levels in untreated SSc strains, whereas in nonaffected skin fibroblasts
TIMP-3 mRNA were reduced down to 54% (p , 0.05) by TNF-α
(Fig 1b). In comparison, TNF-R55 specific TNF-a downregulated
TIMP-2 mRNA levels to 84% in SSc fibroblasts and to 56% (p , 0.005)
in nonaffected skin fibroblasts, whereas the levels of TIMP-1 mRNA
were not markedly altered either in SSc or in nonaffected skin
fibroblasts (Fig 1a, b). Proα1 (I) collagen mRNA levels were reduced
by TNF-R55 specific TNF-α down to 61% (p , 0.005) and 53%
(p , 0.05) of the levels in untreated cultures of SSc and nonaffected
fibroblasts, respectively (Fig 1a, b). Treatment with interleukin-1β
(IL-1β) also significantly reduced TIMP-3 mRNA levels in six SSc
(to 61%, p , 0.005) and in nonaffected skin fibroblast strains (to 71%,
p , 0.05), although to a lesser extent than TNF-α (Fig 1a, c). IL-1β
also downregulated TIMP-2 mRNA levels to 67% in SSc fibroblasts
(p , 0.005) and to 78% in nonaffected fibroblasts, but had no effect
on TIMP-1 mRNA levels (Fig 1a, c).There were no significant
differences in the response of SSc and nonaffected skin fibroblasts to
TNF-α and IL-1β.
TGF-b enhances TIMP-3 mRNA levels in nonaffected and SSc
skin fibroblasts It has been shown that transforming growth factor-
β (TGF-β) is a potent activator of the expression of several ECM
components in dermal fibroblasts (Ka¨ha¨ri, 1993), and that TGF-β1
and TGF-β2 are expressed in scleroderma skin (Kulozik et al, 1990;
Gruschwitz et al, 1990; Peltonen et al, 1990). In addition, TGF-β also
enhances expression of TIMP-3 by cultured WI-38 fibroblasts and
HL-60 myeloid cells (Wick et al, 1994). In this context, we examined
the effect of TGF-β1 on TIMP-3 mRNA levels in SSc and nonaffected
skin fibroblasts. As shown in Fig 2(a, b), the levels of TIMP-3 mRNA
were significantly upregulated by TGF-β1 in both SSc and nonaffected
skin fibroblasts. The mean enhancement of TIMP-3 mRNA abundance
by TGF-β was 8.6-fold (p , 0.05) in six SSc fibroblast strains and
8.1-fold (p , 0.05) in corresponding nonaffected fibroblasts (Fig 2b).
In comparison, TIMP-1 mRNA levels were also induced 2.0- and
2.1-fold (p , 0.01) in SSc and corresponding nonaffected fibroblasts,
respectively (Fig 2a, b). The stimulation of TIMP-1 and TIMP-3
mRNA abundance by TGF-β1 was not significantly different in
nonaffected fibroblasts and SSc fibroblasts.
Activation of TIMP-3 expression in localized scleroderma
skin To examine the activation of TIMP-3 in scleroderma in vivo
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Figure 2. Stimulation of TIMP-3 mRNA expression by TGF-b in SSc
and nonaffected skin fibroblasts. (a) Fibroblasts cultured from nonaffected
(NA-1) and fibrotic (SSc-1) skin of a patient with SSc were maintained in
Dulbecco’s modification of Eagle’s medium containing 1% fetal calf serum for
18 h, and subsequently treated with TGF-β1 (5 ng per ml) for 24 h, as
indicated. Aliquots of total RNA (15 µg) were analyzed for the levels of TIMP-
3, TIMP-1, and GAPDH mRNA with northern blot hybridizations. (b) The
mRNA levels of TIMP-3 and TIMP-1 determined with northern blot
hybridizations were quantitated by densitometric scanning of the autoradiographs
and corrected for the levels of GAPDH mRNA. The bars show the mean 6
SD of mRNA abundance in six nonaffected and SSc fibroblast strains treated
with TGF-β1, relative to the mRNA levels in untreated corresponding fibroblast
strains (1.00). *p , 0.05, **p , 0.01. There were no significant differences in
response to TGF-β between nonaffected and SSc fibroblasts.
we examined TIMP-3 mRNA expression in skin biopsies from patients
with localized scleroderma using in situ hybridization. A prominent
signal for TIMP-3 mRNA was detected in the fibrotic dermal layer
in seven of 12 scleroderma skin samples examined (Table II). The
expression of TIMP-3 mRNA was detected in dermal fibroblasts in
the proximity of mononuclear inflammatory cells (Fig 3A,B,E–G),
but also in fibroblasts embedded in abnormally thickened collagen
fibrils with no apparent contact to inflammatory cells (Fig 3A–C).
Most of the TIMP-3 mRNA positive samples were from indurated
lesions representing the late stage disease characterized by abundant
fibrosis and inflammation, although TIMP-3 mRNA was also detected
in soft lesion with inflammation (Table II). The mean ages of TIMP-
3 positive and negative lesions were 15 mo and 3 mo, respectively,
suggesting that TIMP-3 expression is activated in a later stage in the
development of dermal fibrosis. In accordance with our previous
observations (Airola et al, 1998), no signal for TIMP-3 mRNA was
detected in fibroblasts in normal skin (Fig 3J).
In three of eight localized scleroderma skin samples hybridized with
TIMP-1 anti-sense probe, expression of TIMP-1 mRNA was also
detected in the dermal layer (Table II); however, the number of
fibroblasts expressing TIMP-1 mRNA in these scleroderma skin samples
was lower and their localization was different from those expressing
TIMP-3 mRNA (Fig 3D, H). TIMP-1 positive fibroblasts localized
to the proximity of inflammatory cells, whereas no TIMP-1 mRNA
was noted in fibroblasts in the fibrotic dermal layer (Fig 3D, H). In
addition to dermal fibroblasts, signal for TIMP-1 mRNA was occasion-
ally detected in capillary endothelial cells (Fig 3I). In comparison, we
also examined the expression of collagenase-1 (MMP-1) mRNA in
seven and collagenase-3 (MMP-13) mRNA in five localized sclerod-
erma skin samples, all of which were entirely negative for both MMP-
1 and MMP-13 mRNA (not shown).
DISCUSSION
The results of this study demonstrate that the expression of TIMP-3,
an ECM-associated member of the TIMP gene family, is activated in
SSc skin fibroblasts in culture and in fibrotic localized scleroderma skin
in vivo. In addition, the expression of TIMP-3 mRNA in both SSc
and normal skin fibroblasts is potently enhanced by TGF-β1 and
inhibited by TNF-α. Increased levels of TIMP-1 and TIMP-2 mRNA
were also noted in two SSc fibroblast strains and the expression of
TIMP-1 mRNA was detected in a subset of scleroderma skin samples
in vivo, although at a lower level than TIMP-3. These findings suggest
a role for TIMP-3 in the pathogenesis of dermal fibrosis both in
systemic and in localized scleroderma, possibly in combination with
TIMP-1 and TIMP-2. These observations extend those of previous
reports showing increased production of TIMP-1 by SSc skin fibro-
blasts, as compared with control fibroblasts (Bou Gharios et al, 1994;
Kirk et al, 1995; Kikuchi et al, 1997), and elevated TIMP-1 serum
levels in SSc patients with active disease (Kikuchi et al, 1995). In
addition, SSc skin fibroblasts have been shown to produce less
collagenase-1 (MMP-1) (Takeda et al, 1994) and stromelysin-1 (MMP-
3) (Bou Gharios et al, 1994) than control skin fibroblasts. In this
context, it is interesting to note that MMP-1 and collagenase-3 (MMP-
13) mRNA were not detected in scleroderma skin samples examined
in this study, although both are expressed by dermal fibroblasts in
chronic leg ulcers (Vaalamo et al, 1997).
Expression of TIMP-3 in various cell lines in culture is induced by
mitogenic stimuli, e.g., serum, EGF, and TGF-β, specifically in the
G1 phase of the cell cycle (Leco et al, 1994; Wick et al, 1994, 1995).
In primary human skin fibroblasts, the expression of TIMP-3 is potently
activated by TGF-β as noted in this study, and by platelet derived
growth factor, basic fibroblast growth factor, and epidermal growth
factor (Ahonen et al, unpublished observations). In contrast, expression
of TIMP-3 mRNA is decreased in senescent human fibroblasts (Wick
et al, 1994). Interestingly, in both normal and SSc skin fibroblasts the
expression of TIMP-3 was potently downregulated by TNF-α via
TNF-R55. These observations are in contrast to a previous study
showing stimulation of TIMP-3 expression in murine preneoplastic
JB6 epidermal cell line by TNF-α (Sun et al, 1995), and to our recent
observations in human epidermal keratinocytes, in which TNF-α had
no effect on TIMP-3 expression (Airola et al, 1997), indicating that
the regulation of TIMP-3 gene expression by TNF-α is highly
cell specific.
Using in situ hybridization, TIMP-3 mRNA expression was detected
more often in localized scleroderma skin samples from indurated lesions
histologically classified as the late stage of the disease and characterized
by abundant fibrosis and moderate inflammation, but also in less
indurated lesions with inflammation. TIMP-3 mRNA was expressed
in spindle-shaped fibroblast-like cells in areas of altered collagen and
around blood vessels. Occasional TIMP-3 mRNA positive cells around
vessels were plump shaped and with the hematoxylin and eosin staining
it was not possible to assess whether they were activated fibroblasts or
macrophages; however, expression of TIMP-3 in dermal macrophages
has not been demonstrated so far, whereas our northern blot hybridiza-
tions show that dermal fibroblasts are able to express TIMP-3 mRNA.
As fibroblasts in normal intact skin do not express TIMP-3, it is likely
that TIMP-3 expression by scleroderma skin fibroblasts in vivo indicates
activation of these cells by mitogenic growth factors, e.g., TGF-β.
Expression of TIMP-3 was not uniformly activated in all fibroblasts in
scleroderma skin, but in a subpopulation of fibroblasts both in the
vicinity of inflammatory cell infiltrates and within fibrotic collagenous
ECM. This is in accordance with previous reports showing activation
of type I collagen gene expression in a subpopulation of fibroblasts in
scleroderma skin (Ka¨ha¨ri et al, 1988; Scharffetter et al, 1988). The
proximity of TIMP-3 positive fibroblasts to inflammatory cells suggests
a role for inflammatory cell-derived mediators, e.g., TGF-β in the
activation of fibroblast TIMP-3 expression. As our results show that
TNF-α, a potent inhibitor of ECM formation, also inhibits expression
of TIMP-3 mRNA by dermal fibroblasts, it is possible that the
activation of TIMP-3 expression in scleroderma skin reflects a relative
lack of TNF-α in the extracellular milieu of fibrotic scleroderma
skin; however, marked expression of TIMP-3 mRNA by fibroblasts
embedded in the fibrotic collagenous matrix with no apparent contact
to inflammatory cells, suggests that altered cell–matrix interactions may
also play a role in sustaining TIMP-3 expression at a high level, as has
been reported for type I collagen gene expression in SSc skin fibroblasts
(Ivarsson et al, 1993).
As discussed above, TIMP-3 is associated with the ECM in contrast
to TIMP-1 and TIMP-2, which are secreted in soluble form (Leco
et al, 1994). It is possible that TIMP-3 interacts with specific ECM
components and protects them from degradation by MMP. In addition
to inhibiting MMP activity, both TIMP-1 and TIMP-2 have been
shown to stimulate growth of various types of cells (Hayakawa et al,
1992, 1994), including scleroderma skin fibroblasts (Kikuchi et al,
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Figure 3. Differential activation of TIMP-3 and TIMP-1 expression in scleroderma skin. Sections of scleroderma skin were used for in situ hybridization
with 35S-labeled RNA probes for TIMP-3 and TIMP-1, as described in Materials and Methods. (A,B) Paired dark-field and bright-field exposures show signal for
TIMP-3 mRNA in fibroblasts in the proximity of inflammatory cell infiltrate or embedded in abnormally homogenous collagen. (C) Higher magnification of (B)
showing fibroblasts positive for TIMP-3 mRNA (→) surrounded by homogenous collagen. (D) Dark-field exposure of a section parallel to (A) and (B) hybrididized
with TIMP-1 probe shows the absence of TIMP-1 mRNA in the fibrotic area of the dermis. (E,F) Paired dark- and bright-field exposures of the same scleroderma
skin section showing expression of TIMP-3 mRNA in reticular dermis near the subcutaneous layer (sc) in the proximity of inflammatory cells. (G) Higher
magnification of (F) showing TIMP-3 mRNA positive fibroblasts (→). (H) A section parallel to (E) and (F) was hybridized with TIMP-1 anti-sense probe.
Scattered expression of TIMP-1 mRNA is noted in the vicinity of inflammatory cells. (I) Expression of TIMP-1 mRNA in endothelial cells (arrowheads). (J) No
signal for TIMP-3 mRNA is detected in the dermal layer of normal skin. The time for autoradiography was 10–30 d. Scale bars: (A, B, D) 10 µm; (C, G, I) 6 µm;
(E, F, H, J) 24 µm.
1997). It has also been shown that TIMP-3 stimulates proliferation of
fibroblasts and that in chicken fibroblasts the expression of TIMP-3 is
induced by transformation (Staskus et al, 1991; Yang and Hawkes,
1992). It is possible that matrix-associated TIMP-3 as well as soluble
TIMP-1 and TIMP-2 stimulate the growth of dermal fibroblasts in vivo
in an autocrine or paracrine manner, and thus contribute to the
expansion of the activated fibroblast population during the development
of dermal fibrosis.
The role of ECM turnover has also been examined in other forms
of tissue fibrosis. Elevated levels of TIMP-1 and TIMP-2 mRNA have
been detected in rat and human hepatic fibrosis (Iredale et al, 1996;
Herbst et al, 1997) and in rat renal fibrosis (Ishidoya et al, 1996).
Furthermore, increased expression of TIMP-2 mRNA has been
observed in human chronic pancreatitis characterized by deposition of
ECM components (Gress et al, 1994). In addition, elevated serum
TIMP-1 levels appear to correlate with the degree of hepatic fibrosis
in patients with liver cirrhosis (Murawaki et al, 1993; Muzzillo et al,
1993). Together, these observations, along with the results of this study,
suggest that an alteration in the balance between activated MMP and
their specific inhibitors (TIMP) is a general phenomenon in tissue
fibrosis, and warrants examination of TIMP-3 expression in other
fibrotic conditions besides scleroderma.
In conclusion, the results presented in this study demonstrate for
the first time that expression of the ECM-associated member of the
TIMP gene family, TIMP-3, is specifically upregulated in systemic
scleroderma skin fibroblasts in culture and in localized scleroderma
skin in vivo, whereas TIMP-1 expression is activated to a lesser extent.
These results provide supporting in vitro and in vivo evidence for the
concept of reduced ECM turnover in the pathogenesis of dermal
fibrosis, and suggest a role for TIMP-3 in this process via inhibition
of degradation of fibrotic ECM. In addition, our results show that
fibroblast TIMP-3 gene expression is stimulated by TGF-β and
inhibited by TNF-α and IL-1β, which also potently stimulate and
inhibit expression of type I collagen, respectively. It is therefore likely
that marked expression of TIMP-3 by fibroblasts in fibrotic scleroderma
skin indicates stimulation of these cells by TGF-β and possibly other
fibroblast mitogens, as well as a lack of exposure to TNF-α. Although
these results provide evidence for similar activation of TIMP-3 expres-
sion in both systemic and localized scleroderma, it is also good to keep
in mind the fundamental differences in the pathogenesis of these
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two distinct forms of dermal fibrosis. Nevertheless, together these
observations provide new insight to the pathogenesis of cutaneous
fibrosis and may be feasible in the development of novel therapeutic
strategies for treatment of systemic and localized scleroderma and other
fibrotic disorders.
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